SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-000576
Filing Date
2023-01-10
Accepted
2023-01-10 09:00:11
Documents
15
Period of Report
2023-01-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20230110.htm   iXBRL 8-K 59350
2 EX-99.1 sabs-ex99_1.htm EX-99.1 19520
3 GRAPHIC img1871078_0.jpg GRAPHIC 10467
  Complete submission text file 0000950170-23-000576.txt   250490

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sabs-20230110_def.xml EX-101.DEF 13467
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sabs-20230110.xsd EX-101.SCH 3214
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sabs-20230110_lab.xml EX-101.LAB 17250
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sabs-20230110_pre.xml EX-101.PRE 12759
9 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20230110_htm.xml XML 6479
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 23519781
SIC: 2836 Biological Products, (No Diagnostic Substances)